In 833 adults aged ≥50, giving adjuvanted RSVPreF3 with an XBB.1.5 COVID-19 mRNA vaccine met non-inferiority for RSV-A and RSV-B titres vs sequential dosing but marginally missed it for SARS-CoV-2 (GMT ratio 1.31, 95% CI 1.13–1.51); safety was similar.
RCTn = 833
Bonten et al. Immunogenicity and Safety of Coadministration of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine and a COVID-19 mRNA Vaccine in Adult s Aged ≥50 Years: A Phase 3, Randomized, Noninferiority Trial